Posts
Dualsystems Biotech partners with IBR Inc. to validate the workflow of the CaptiRec Technology
/in News /by heleneDualsystems Biotech AG Press Release
Dualsystems Biotech partners with IBR Inc. to validate the workflow of the CaptiRec Technology
Schlieren, Switzerland, January 2014: – Dualsystems Biotech AG has announced it will collaborate with another Swiss laboratory, Institute for Biopharmaceutical Research (IBR Inc.) to validate the CaptiRec Triceps/Ligand Receptor Capture Technology. This technology is used to identify the Cell Membrane Receptors on Living Cells.
The partnership will combine the respective strengths of Dualsystems, a leading service provider for protein interaction at the cell membrane and IBR Inc., a GLP-compliant contract research organization specializing in cell-based assays
Video interview about CaptiRec Services (LRC)
/0 Comments/in News /by heleneVideo interview of CaptiRec Services, ligand-receptor capture technology (LRC) with Dr. Paul Helbling, the new management of Dualsystems Biotech AG.
Licensing Agreement with ETH Zurich on LRC technoloy
/0 Comments/in News /by heleneDualsystems Biotech closes Licensing Agreement with ETH Zurich on Ligand Receptor Capture (LRC) technology
Dualsystems Biotech has licensed an innovative technology to discover cell-surface receptors for a vast range of ligands of interest. LRC is centered around an innovative trifunctional chemoproteomic reagent named TriCEPS™, which enables the unbiased identification of cell surface receptors for many types of ligands, such as peptides, proteins, antibodies, engineered affinity binders or viruses. Receptor capture takes place under near-physiological conditions on native tissues and cells, without the need for genetic manipulations. Read more
Pages
Protected: Manual
/Enter your password to view comments./by heleneDualsystems
LRC TriCEPS Service
Dualsystems Biotech AG
Dr. Paul Helbling
Grabenstrasse 11a
8952 Schlieren
Switzerland
phone +41 44 738 50 00
fax +41 44 738 50 05